BPC-157 (Body Protection Compound-157)
Sleep & Recovery · Pentadecapeptide
Tier D
Bottom line
Read Off Label grades BPC-157 (Body Protection Compound-157) as D (2.9/10) based on preclinical only evidence, variable benefit magnitude, and a unknown-high-risk safety profile.
The canonical 'biohacker healing peptide.
Typical use: 250-500 mcg subQ 1-2x daily (anecdotal); also oral capsule forms — Not FDA-approved; FDA classified as Category 2 on interim 503A bulks list — prohibited from US compounding pharmacies per Jan 7, 2025 final guidance; WADA-banned; sold as research peptide; removed from the Category 2 interim list April 2026 (nominators withdrew), with an FDA Pharmacy Compounding Advisory Committee review of BPC-157 for the 503A bulks list set for July 23, 2026.
What this is
The canonical 'biohacker healing peptide.' Extensive Sikiric preclinical work on tendon, ligament, GI healing. Zero published human RCTs. FDA Jan 2025 final guidance ended legal US compounding access (previously a gray-zone). Ongoing litigation (Evexias/Farmakeio) challenging the FDA process. Widely anecdotally reported to accelerate tendon/joint recovery; evidence base remains preclinical. Treat consumer supply as unverified research-peptide exposure, not a regulated medication. April 2026: FDA removed BPC-157 from the Category 2 interim 503A list after the nominations were withdrawn; a Pharmacy Compounding Advisory Committee (PCAC) meeting is set for July 23, 2026 to review it for the 503A compounding bulks list - the next decision point on legal compounding access.
Mechanism
Synthetic fragment of a gastric 'body protection' protein; proposed pro-angiogenic via VEGFR2 pathway; nitric oxide pathway modulation; reported tendon/ligament/GI healing in rodent models
Dose & route
250-500 mcg subQ 1-2x daily (anecdotal); also oral capsule forms
Citations
- https://pubmed.ncbi.nlm.nih.gov/33799484/
- https://pubmed.ncbi.nlm.nih.gov/30915550/
- https://www.fda.gov/media/174456/download
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does BPC-157 (Body Protection Compound-157) work?
- Read Off Label rates the evidence for BPC-157 (Body Protection Compound-157) as Preclinical only and the benefit magnitude as variable, producing an overall grade of D (2.9/10). The canonical 'biohacker healing peptide.
- Is BPC-157 (Body Protection Compound-157) safe?
- BPC-157 (Body Protection Compound-157) has a unknown-high risk profile in published human data. Legal status: Not FDA-approved; FDA classified as Category 2 on interim 503A bulks list — prohibited from US compounding pharmacies per Jan 7, 2025 final guidance; WADA-banned; sold as research peptide; removed from the Category 2 interim list April 2026 (nominators withdrew), with an FDA Pharmacy Compounding Advisory Committee review of BPC-157 for the 503A bulks list set for July 23, 2026. This is not medical advice — see the disclaimer.
- What is the typical dose for BPC-157 (Body Protection Compound-157)?
- 250-500 mcg subQ 1-2x daily (anecdotal); also oral capsule forms
- How does BPC-157 (Body Protection Compound-157) work?
- Synthetic fragment of a gastric 'body protection' protein; proposed pro-angiogenic via VEGFR2 pathway; nitric oxide pathway modulation; reported tendon/ligament/GI healing in rodent models
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.